Cargando…

Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population

Background. A number of US observational studies reported an increased mortality risk with higher intact parathyroid hormone (iPTH), calcium and/or phosphate. The existence of such a link in a European haemodialysis population was explored as part of the Analysing Data, Recognising Excellence and Op...

Descripción completa

Detalles Bibliográficos
Autores principales: Floege, Jürgen, Kim, Joseph, Ireland, Elizabeth, Chazot, Charles, Drueke, Tilman, de Francisco, Angel, Kronenberg, Florian, Marcelli, Daniele, Passlick-Deetjen, Jutta, Schernthaner, Guntram, Fouqueray, Bruno, Wheeler, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107766/
https://www.ncbi.nlm.nih.gov/pubmed/20466670
http://dx.doi.org/10.1093/ndt/gfq219
_version_ 1782205241492504576
author Floege, Jürgen
Kim, Joseph
Ireland, Elizabeth
Chazot, Charles
Drueke, Tilman
de Francisco, Angel
Kronenberg, Florian
Marcelli, Daniele
Passlick-Deetjen, Jutta
Schernthaner, Guntram
Fouqueray, Bruno
Wheeler, David C.
author_facet Floege, Jürgen
Kim, Joseph
Ireland, Elizabeth
Chazot, Charles
Drueke, Tilman
de Francisco, Angel
Kronenberg, Florian
Marcelli, Daniele
Passlick-Deetjen, Jutta
Schernthaner, Guntram
Fouqueray, Bruno
Wheeler, David C.
author_sort Floege, Jürgen
collection PubMed
description Background. A number of US observational studies reported an increased mortality risk with higher intact parathyroid hormone (iPTH), calcium and/or phosphate. The existence of such a link in a European haemodialysis population was explored as part of the Analysing Data, Recognising Excellence and Optimising Outcomes (ARO) Chronic Kidney Disease (CKD) Research Initiative. Methods. The association between the markers of mineral and bone disease and clinical outcomes was examined in 7970 patients treated in European Fresenius Medical Care facilities over a median of 21 months. Baseline and time-dependent (TD) Cox regression were performed using Kidney Disease Outcomes Quality Initiative (KDOQI) target ranges as reference categories, adjusting for demographics, medical history, dialysis parameters, inflammation, medications and laboratory parameters. Fractional polynomial (FP) models were also used. Results. Hazard ratio (HR) estimates from baseline analysis for iPTH were U-shaped [>600 pg/mL, HR = 2.10, 95% confidence interval (CI) 1.62–2.73; <75 pg/mL, HR = 1.46, 95% CI 1.17–1.83]. TD analysis confirmed the results for iPTH. Baseline analysis showed that calcium >2.75 mmol/L increased risk of death (HR = 1.70, 95% CI 1.19–2.42). TD analysis showed that both low (HR = 1.19, 95% CI 1.04–1.37) and high calcium (HR = 1.74, 95% CI 1.30–2.34) increased risk of death. Baseline analysis for phosphate showed a U-shaped pattern (<1.13 mmol/L, HR = 1.18, 95% CI 1.01–1.37; >1.78 mmol/L, HR = 1.32, 95% CI 1.13–1.55). TD analysis confirmed the results for phosphate <1.13 mmol/L. HR estimates were higher in patients with diabetes versus those without diabetes for baseline analysis only (P-value = 0.014). FP analysis confirmed the results of baseline and TD analyses. Conclusion. Patients with iPTH, calcium and phosphate levels within the KDOQI target ranges have the lowest risk of mortality compared with those outside the target ranges.
format Online
Article
Text
id pubmed-3107766
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-31077662011-06-06 Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population Floege, Jürgen Kim, Joseph Ireland, Elizabeth Chazot, Charles Drueke, Tilman de Francisco, Angel Kronenberg, Florian Marcelli, Daniele Passlick-Deetjen, Jutta Schernthaner, Guntram Fouqueray, Bruno Wheeler, David C. Nephrol Dial Transplant Original Article Background. A number of US observational studies reported an increased mortality risk with higher intact parathyroid hormone (iPTH), calcium and/or phosphate. The existence of such a link in a European haemodialysis population was explored as part of the Analysing Data, Recognising Excellence and Optimising Outcomes (ARO) Chronic Kidney Disease (CKD) Research Initiative. Methods. The association between the markers of mineral and bone disease and clinical outcomes was examined in 7970 patients treated in European Fresenius Medical Care facilities over a median of 21 months. Baseline and time-dependent (TD) Cox regression were performed using Kidney Disease Outcomes Quality Initiative (KDOQI) target ranges as reference categories, adjusting for demographics, medical history, dialysis parameters, inflammation, medications and laboratory parameters. Fractional polynomial (FP) models were also used. Results. Hazard ratio (HR) estimates from baseline analysis for iPTH were U-shaped [>600 pg/mL, HR = 2.10, 95% confidence interval (CI) 1.62–2.73; <75 pg/mL, HR = 1.46, 95% CI 1.17–1.83]. TD analysis confirmed the results for iPTH. Baseline analysis showed that calcium >2.75 mmol/L increased risk of death (HR = 1.70, 95% CI 1.19–2.42). TD analysis showed that both low (HR = 1.19, 95% CI 1.04–1.37) and high calcium (HR = 1.74, 95% CI 1.30–2.34) increased risk of death. Baseline analysis for phosphate showed a U-shaped pattern (<1.13 mmol/L, HR = 1.18, 95% CI 1.01–1.37; >1.78 mmol/L, HR = 1.32, 95% CI 1.13–1.55). TD analysis confirmed the results for phosphate <1.13 mmol/L. HR estimates were higher in patients with diabetes versus those without diabetes for baseline analysis only (P-value = 0.014). FP analysis confirmed the results of baseline and TD analyses. Conclusion. Patients with iPTH, calcium and phosphate levels within the KDOQI target ranges have the lowest risk of mortality compared with those outside the target ranges. Oxford University Press 2011-06 2010-04-25 /pmc/articles/PMC3107766/ /pubmed/20466670 http://dx.doi.org/10.1093/ndt/gfq219 Text en © The Author 2010. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org http://creativecommons.org/licenses/by-nc/2.5 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Floege, Jürgen
Kim, Joseph
Ireland, Elizabeth
Chazot, Charles
Drueke, Tilman
de Francisco, Angel
Kronenberg, Florian
Marcelli, Daniele
Passlick-Deetjen, Jutta
Schernthaner, Guntram
Fouqueray, Bruno
Wheeler, David C.
Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population
title Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population
title_full Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population
title_fullStr Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population
title_full_unstemmed Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population
title_short Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population
title_sort serum ipth, calcium and phosphate, and the risk of mortality in a european haemodialysis population
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107766/
https://www.ncbi.nlm.nih.gov/pubmed/20466670
http://dx.doi.org/10.1093/ndt/gfq219
work_keys_str_mv AT floegejurgen serumipthcalciumandphosphateandtheriskofmortalityinaeuropeanhaemodialysispopulation
AT kimjoseph serumipthcalciumandphosphateandtheriskofmortalityinaeuropeanhaemodialysispopulation
AT irelandelizabeth serumipthcalciumandphosphateandtheriskofmortalityinaeuropeanhaemodialysispopulation
AT chazotcharles serumipthcalciumandphosphateandtheriskofmortalityinaeuropeanhaemodialysispopulation
AT drueketilman serumipthcalciumandphosphateandtheriskofmortalityinaeuropeanhaemodialysispopulation
AT defranciscoangel serumipthcalciumandphosphateandtheriskofmortalityinaeuropeanhaemodialysispopulation
AT kronenbergflorian serumipthcalciumandphosphateandtheriskofmortalityinaeuropeanhaemodialysispopulation
AT marcellidaniele serumipthcalciumandphosphateandtheriskofmortalityinaeuropeanhaemodialysispopulation
AT passlickdeetjenjutta serumipthcalciumandphosphateandtheriskofmortalityinaeuropeanhaemodialysispopulation
AT schernthanerguntram serumipthcalciumandphosphateandtheriskofmortalityinaeuropeanhaemodialysispopulation
AT fouqueraybruno serumipthcalciumandphosphateandtheriskofmortalityinaeuropeanhaemodialysispopulation
AT wheelerdavidc serumipthcalciumandphosphateandtheriskofmortalityinaeuropeanhaemodialysispopulation
AT serumipthcalciumandphosphateandtheriskofmortalityinaeuropeanhaemodialysispopulation